How to Invest in Intuitive Surgical, Inc. (ISRG)
Short answer
You can invest in Intuitive Surgical (ISRG) by buying shares or fractional shares at any major broker, through a healthcare or medical-device ETF, or as one holding in a thematic basket. Intuitive is the dominant surgical-robotics company; the da Vinci system creates a razor-and-blade model where recurring instrument and service revenue compounds as procedures grow. That gives ISRG a wide moat and high-quality recurring revenue, so it tends to behave as a premium-valued medtech compounder rather than a cheap value name.
What does Intuitive Surgical, Inc. (ISRG) do?
Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Its business model is razor-and-blade: Intuitive sells or places the large capital systems, then earns high-margin recurring revenue from the single-use instruments and accessories consumed in each procedure, plus service contracts. As the installed base of systems grows and procedure volumes rise, recurring revenue compounds. The company has expanded its platform with newer systems (including the da Vinci 5 and the Ion platform for lung biopsy), and benefits from surgeon training, hospital workflow integration, and a large library of validated procedures that create high switching costs. Intuitive went public in 2000 and is headquartered in Sunnyvale, California. It is the clear leader in surgical robotics with a wide moat, strong margins, and consistent procedure-volume growth, though it trades at a premium valuation that reflects those qualities.
What's driving Intuitive Surgical, Inc. (ISRG)?
1. Razor-and-blade recurring revenue.
Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. As the installed base and procedure volumes grow, this recurring stream compounds with high margins and far more predictability than one-time capital sales.
2. Installed base and switching costs.
Hospitals invest heavily in da Vinci systems, surgeon training, and workflow integration, which creates strong switching costs and a durable relationship. A growing global installed base of systems expands the addressable procedure pool each year and gives Intuitive a platform to introduce new procedures and instruments.
3. Platform expansion and new procedures.
Newer systems like da Vinci 5 and the Ion robotic bronchoscopy platform for lung biopsy extend Intuitive's reach into additional specialties. Each newly validated procedure type and geographic expansion broadens the runway for procedure growth, supported by clinical evidence and surgeon adoption.
What are the risks to Intuitive Surgical, Inc. (ISRG)?
ISRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. Competition is intensifying as Medtronic, Johnson & Johnson, and others develop rival surgical-robotics platforms that could erode Intuitive's dominance over time. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends and currency, and the high valuation leaves little room for execution missteps.
How is Intuitive Surgical, Inc. (ISRG) valued? (approximate, early 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Intuitive Surgical, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$8 to 9 billion (verify)
- Recurring revenue share: ~80%+ from instruments, accessories, and service
- Operating margin: ~30% (strong)
- Gross margin: ~65% to 68%
- P/E (TTM): ~60x to 75x (premium; verify)
- Dividend: Initiated a modest dividend recently (verify status and yield)
- Procedure growth: High-single to low-double-digit annual growth
- Balance sheet: Strong; large net cash position
Intuitive trades at a high earnings multiple that reflects its dominant market position, high-margin recurring revenue, strong balance sheet, and consistent procedure-volume growth. The premium is the central debate: bulls justify it with the durability of the razor-and-blade model and a long runway, while bears point to multiple-compression risk if procedure growth slows or competitors gain share. Figures are approximate and should be verified against the latest filing.
Which ETFs hold Intuitive Surgical, Inc. (ISRG)?
If you want ISRG exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.
| ETF | Name | % in ISRG | Expense ratio | |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR Fund | ~4% | 0.08% |
What themes does Intuitive Surgical, Inc. (ISRG) fit?
These are the investment theses ISRG naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.
Who competes with Intuitive Surgical, Inc. (ISRG)?
Surgical robotics
Medtronic (Hugo platform) and Johnson & Johnson (Ottava, via Ethicon) are developing rival soft-tissue surgical-robotics systems aimed at Intuitive's core market. Several smaller and regional players and startups are also pursuing robotic surgery, though none has yet matched da Vinci's installed base or procedure breadth.
Conventional and laparoscopic surgery
Traditional minimally invasive (laparoscopic) and open-surgery instruments from Medtronic, Johnson & Johnson (Ethicon), and others compete on cost where robotic assistance is not deemed necessary. The broader debate is when robotic assistance justifies its premium versus established laparoscopic techniques.
Adjacent diagnostics and intervention
In robotic bronchoscopy and lung diagnostics, Intuitive's Ion competes with platforms such as Johnson & Johnson's Monarch, plus conventional biopsy and navigation techniques.
What stocks are similar to Intuitive Surgical, Inc. (ISRG)?
Other names that show up alongside ISRG in the same themes. Worth a look if you're thinking about diversification within a single thesis rather than concentration on one ticker.
Also fits Humanoid robotics. Tesla's Optimus is among the most-watched humanoid programs, built on the company's autonomy, vision, and manufacturing stack.
Also fits Humanoid robotics. Supplies the training compute, Isaac simulation platform, and on-robot inference chips that many humanoid programs depend on.
Also fits Humanoid robotics. One of the world's largest industrial robotics and automation companies; deep actuation and motion-control expertise.
Also fits Humanoid robotics. Rockwell Automation supplies the control systems and industrial software that factory robotics, including humanoid pilots, run on.
How to invest in Intuitive Surgical, Inc. (ISRG)
There are three common ways to get ISRG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (XLV), which spreads the position across many companies. Or build it into a focused thematic basket, so ISRG sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where ISRG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical (ISRG) is a wide-moat medtech compounder whose recurring instrument and service revenue grows with procedure volume on a large installed base. In a portfolio it behaves as a high-quality healthcare growth holding with strong margins and durable demand, balanced by a premium valuation, which is how most long-term holders frame it.
Build a basket around ISRG with Walnut
Use Intuitive Surgical, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is Intuitive Surgical's ticker symbol?
+
ISRG, listed on Nasdaq. The company is Intuitive Surgical, Inc., headquartered in Sunnyvale, California. It went public in 2000 and trades during US market hours at every major US brokerage.
What does Intuitive Surgical do?
+
Intuitive Surgical makes robotic-assisted surgery systems, most notably the da Vinci platform used for minimally invasive procedures in urology, gynecology, general surgery, and other specialties. It also makes the Ion platform for robotic lung biopsy. It earns most revenue from single-use instruments, accessories, and service, not just system sales.
Why is ISRG considered a high-quality stock?
+
Intuitive has a razor-and-blade model where recurring, high-margin revenue from instruments and service grows with procedure volume on a large installed base. High switching costs, strong margins, a clean balance sheet, and consistent procedure growth give it a wide moat that investors value highly.
Who are Intuitive Surgical's competitors?
+
In surgical robotics, Medtronic (Hugo) and Johnson & Johnson (Ottava) are developing rival systems. Traditional laparoscopic instruments from Medtronic and J&J's Ethicon compete where robotics is not used. In robotic bronchoscopy, Intuitive's Ion competes with platforms like J&J's Monarch.
Does Intuitive Surgical pay a dividend?
+
Intuitive historically did not pay a dividend and prioritized reinvestment and buybacks, but it initiated a modest dividend more recently. Verify the current dividend status and yield against the latest company filings, as the figure is approximate and can change.
Is ISRG expensive?
+
ISRG trades at a premium earnings multiple, often in the 60x to 75x range as of early 2026, which is high relative to the broader market. The premium reflects its dominant position, recurring high-margin revenue, and growth, but it also means the stock carries multiple-compression risk if growth slows. The figure is approximate.
How does Intuitive Surgical make money?
+
Most revenue comes from recurring sources: the single-use instruments and accessories consumed in each da Vinci procedure, plus multi-year service contracts on installed systems. System sales themselves are a smaller and lumpier part of revenue, so growth tracks procedure volume on the installed base.
What is the da Vinci system?
+
The da Vinci is Intuitive's flagship robotic-assisted surgery platform. A surgeon controls robotic arms and instruments from a console to perform minimally invasive procedures with enhanced precision and visualization. Newer generations include the da Vinci 5, and the company also sells the Ion platform for lung biopsy.
Is Intuitive Surgical in the S&P 500?
+
Yes. Intuitive Surgical is a constituent of the S&P 500 and is one of the larger medical-device companies by market cap. It appears in many broad-index and healthcare-sector ETFs as a notable holding.
Which ETFs hold ISRG?
+
Broad index funds like VOO and SPY hold Intuitive Surgical as an S&P 500 constituent. Healthcare-sector ETFs such as XLV and medical-device-focused funds like IHI typically hold ISRG at meaningful weights given its size within the medtech category.
Is ISRG a good stock to buy?
+
Descriptive, not a recommendation. Intuitive Surgical offers a dominant surgical-robotics franchise, high-margin recurring revenue, a wide moat, and consistent procedure growth, balanced against a premium valuation, rising competition from Medtronic and Johnson & Johnson, and hospital-budget cyclicality. Whether it fits a given portfolio depends on your goals, time horizon, and risk tolerance. Walnut is informational, not investment advice.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Intuitive Surgical, Inc.'s investor relations page or your broker before making investment decisions.